$ABBV ▲ +0.0% - AbbVie Inc. $ABBV Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease 27-AUG-2026 09:14 AM